Table 3.
Detailed profile of double hit (+) diffuse large B cell lymphoma patients.
| No. | Age | Stage | R-IPI | Bulky | DE | Frontline Treatment | CR | Alive | Cause of Death | PFS (Days) | OS (Days) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 75 | 4 | 5 | Yes | Yes | Palliative care | No | No | Disease related | 14 | 14 |
| 2 | 64 | 1 | 1 | No | No | R-CHOP × 6 | Yes | Yes | 1203 | 1203 | |
| 3 | 75 | 2 | 2 | Yes | No | R-COP × 8 | No | No | Disease related | 257 | 368 |
| 4 | 67 | 3 | 2 | Yes | No | R-CHOP × 4 | Yes | No | Hepatitis B flare-up | 174 | 174 |
| 5 | 54 | 4 | 2 | No | No | R-CHOP × 8 | Yes | Yes | 1176 | 1176 | |
| 6 | 77 | 3 | 3 | Yes | No | R-COP × 2 | No | No | Disease related | 85 | 85 |
| 7 | 54 | 4 | 2 | No | Yes | (R-CHOP + IT) × 5 | Yes | No | Septic shock | 128 | 128 |
| 8 | 46 | 4 | 2 | No | No | (R-CHOP + IT, R-MA) × 2 | No | No | Disease related | 223 | 275 |
| 9 | 80 | 4 | 4 | Yes | Yes | Palliative care | No | No | Disease related | 43 | 43 |
| 10 | 71 | 3 | 4 | Yes | No | R-CEOP × 5 | No | No | Disease related | 158 | 401 |
| 11 | 48 | 4 | 3 | Yes | Yes | R-CHOP × 1 | No | No | Disease related | 58 | 134 |
| 12 | 70 | 4 | 3 | Yes | Yes | R-CHOP × 6 | Yes | Yes | 866 | 866 | |
| 13 | 66 | 4 | 3 | No | Yes | R-CHOP × 6 | Yes | No | Aortic stenosis with heart failure | 199 | 199 |
| 14 | 41 | 3 | 3 | Yes | Yes | R-EPOCH × 6 | Yes | Yes | 1157 | 1157 |
R-IPI: revised International Prognostic Index; DE: double expresser; CR: complete remission; PFS: progression-free survival; OS: overall survival; IT: intrathecal chemotherapy; R-CHOP: rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone; R-COP: rituximab, cyclophosphamide, vincristine, prednisone; R-EPOCH: rituximab, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin; R-MA: rituximab, methotrexate, cytarabine.